In-vitro susceptibility of ESBL producing Gram negative bacilli to ceftriaxone-sulbactam-disodium-EDTA combination in a north IIndian tertiary care hospital.
Bali, N., Mir, A., Bali, R., Gani, T., Mathew, D., Jan, I., Ramakrishnan, S., Nisar, Q., Ahmed, T. (2025). In-vitro susceptibility of ESBL producing Gram negative bacilli to ceftriaxone-sulbactam-disodium-EDTA combination in a north IIndian tertiary care hospital.. EKB Journal Management System, (), -. doi: 10.21608/mid.2025.366254.2606
Nargis Bali; Anjum Ara Mir; Roseleen Bali; Tantray Faisal Gani; Dona Mathew; Iram Jan; Susheem Ramakrishnan; Qounser Nisar; Tufail Ahmed. "In-vitro susceptibility of ESBL producing Gram negative bacilli to ceftriaxone-sulbactam-disodium-EDTA combination in a north IIndian tertiary care hospital.". EKB Journal Management System, , , 2025, -. doi: 10.21608/mid.2025.366254.2606
Bali, N., Mir, A., Bali, R., Gani, T., Mathew, D., Jan, I., Ramakrishnan, S., Nisar, Q., Ahmed, T. (2025). 'In-vitro susceptibility of ESBL producing Gram negative bacilli to ceftriaxone-sulbactam-disodium-EDTA combination in a north IIndian tertiary care hospital.', EKB Journal Management System, (), pp. -. doi: 10.21608/mid.2025.366254.2606
Bali, N., Mir, A., Bali, R., Gani, T., Mathew, D., Jan, I., Ramakrishnan, S., Nisar, Q., Ahmed, T. In-vitro susceptibility of ESBL producing Gram negative bacilli to ceftriaxone-sulbactam-disodium-EDTA combination in a north IIndian tertiary care hospital.. EKB Journal Management System, 2025; (): -. doi: 10.21608/mid.2025.366254.2606

In-vitro susceptibility of ESBL producing Gram negative bacilli to ceftriaxone-sulbactam-disodium-EDTA combination in a north IIndian tertiary care hospital.

Microbes and Infectious Diseases
Articles in Press, Accepted Manuscript, Available Online from 04 July 2025  XML
Document Type: Original Article
DOI: 10.21608/mid.2025.366254.2606
View on SCiNiTO View on SCiNiTO
Authors
Nargis Bali1; Anjum Ara Mir email 1; Roseleen Bali2; Tantray Faisal Gani1; Dona Mathew3; Iram Jan1; Susheem Ramakrishnan1; Qounser Nisar1; Tufail Ahmed4
1Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Soura, India
2Department of Respiratory and Pulmonary Medicine, Apollo Hospital, New Delhi, India
3Department of Microbiology, Sher-i-Kashmir Institute of Medical Sciences, Soura. India
4Department of Microbiology Govt Medical College, Anantnag, India
Abstract
Background: The study was undertaken to evaluate the in-vitro efficacy of Ceftriaxone-sulbactam- EDTA (CSE) combination in clinical isolates of GNB especially those expressing extended spectrum beta lactamase (ESBL) and to compare the sensitivity of CSE to meropenem. Methods: Clinical samples received in our laboratory from patients admitted at our hospital from January 2024 to June 2024 were processed for the recovery of Gram negative bacilli (GNB). The antimicrobial susceptibility of these isolates was performed by disc diffusion method and ESBL production confirmed by combined disc susceptibility test (CDST) as per guidelines. Statistical analysis was done by SPSS v 22. Results: A total of 672 GNB were part of the study. Majority of the isolates were recovered from pus samples and the most common GNB recovered was Acinetobacter baumannii. The GNB exhibited variable sensitivity to the tested antibiotics. ESBL production was seen in 30.2% of GNB. Overall sensitivity of CSE in GNB was 89.7% and it was 87.7% in ESBL producing isolates. Meropenem was sensitive in 71% GNB and 29% isolates were resistant to it. All meropenem sensitive GNB were sensitive to CSE as well and 64.6% meropenem resistant isolates were found to be sensitive to CSE. Conclusion: CSE can be used as a carbapenem sparing agent and can also be a part of the empirical drug regimen in place for patients suffering from bacterial infections at our hospital.
Keywords
Antimicrobial resistance; Adjuvants; Carbapenems; Gram negative bacilli
Statistics
Article View: 69